Welcome to our dedicated page for Entero Therapeutics news (Ticker: ENTO), a resource for investors and traders seeking the latest updates and insights on Entero Therapeutics stock.
News for Entero Therapeutics, Inc. (NASDAQ: ENTO) covers a company that combines late clinical-stage biopharmaceutical development with a growing presence in AI-driven energy and digital infrastructure. Company press releases describe Entero’s ongoing work on Adrulipase, a recombinant lipase enzyme for gastrointestinal indications, alongside a strategic expansion into grid-edge software and data-center power orchestration through its wholly owned subsidiary, Grid AI.
Recent ENTO news highlights several major themes. First, Entero announced the acquisition of 100% of Grid AI Corp, characterized as a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources. Subsequent releases detail Grid AI’s Dynamic Load Shaping™, Aggregation Management Platform, and plans to support hyperscale AI data centers with power-cluster optimization, campus orchestration, and AI data-center controls.
Investors following ENTO-related news will also see updates on corporate identity and listing status. The company has reported regaining compliance with Nasdaq’s stockholders’ equity requirement following the Grid AI share exchange and has announced an intended corporate name change to GridAI Technologies Corp. with a new ticker symbol, GRDX, to better reflect its combined focus on AI, data centers, and grid-edge orchestration.
Additional news items describe Grid AI’s letters of intent with a hyperscaler AI data-center developer in the ERCOT market, integration of engineering teams such as LV Grid, and the build-out of a U.S.-based leadership team with experience in energy, power, and technology. Together, these disclosures provide a stream of updates on Entero’s GI drug development, capital markets activity, and its evolving role at the intersection of AI workloads, power grids, and digital infrastructure.
Entero Therapeutics (NASDAQ: ENTO) has announced the acquisition of GRID AI Corp, a grid-edge AI platform company, marking a strategic pivot into the AI energy infrastructure market. GRID AI's platform, which has received over $50 million in investment since 2019, specializes in Dynamic Load Shaping and Aggregation Management for behind-the-meter energy assets.
The transaction structure will result in GRID AI shareholders owning 82.5% of ENTO's fully diluted common stock, while existing ENTO shareholders will retain 17.5%. The deal includes board restructuring, with GRID AI shareholders initially appointing two directors and eventually controlling five of seven board seats.
This strategic acquisition positions ENTO in a high-growth market, as Goldman Sachs projects global data-center power demand to increase by ~50% by 2027 and up to 165% by 2030 versus 2023 levels, driven by AI infrastructure expansion.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on GI disease therapies, announced a 1-for-3 reverse stock split effective August 18, 2025. The split will reduce outstanding shares from 4.77 million to approximately 1.59 million.
The reverse split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Stockholders will receive cash in lieu of fractional shares. The company's interim CEO emphasized that maintaining Nasdaq listing visibility is crucial for enhancing shareholder value.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on GI diseases, has secured a $3 million private placement through the sale of pre-funded and common warrants. The offering includes 4,878,841 pre-funded warrants and 9,757,682 common warrants, with a combined purchase price of $0.6149 for one pre-funded warrant and two common warrants.
The pre-funded warrants have an exercise price of $0.00001 and are immediately exercisable. The common warrants, exercisable at $0.3649 per share, have a 5-year term. The company will receive $1 million at closing and the remaining $2 million upon registration statement effectiveness. The transaction is expected to close around August 11, 2025.
Entero Therapeutics (NASDAQ: ENTO) has announced signing a rescission agreement to unwind its business combination with ImmunogenX, (IMGX). The combination, originally announced on December 18, 2023, and closed on March 14, 2024, will be reversed pending shareholder approval required by June 30, 2025.
The company's CEO, Richard Paolone, stated that the decision to unwind the transaction was made following an internal review, aimed at strengthening the balance sheet and refocusing value creation strategy. The rescission will allow both companies to pursue independent strategic initiatives while maintaining a positive working relationship.
Additionally, Entero announced the appointment of Anna Skowron as Chief Financial Officer, effective March 3, 2025. Skowron brings 14 years of accounting experience, including expertise in financial reporting, compliance, and business strategy. She previously founded Skowron Accounting Professional and held positions as Global Financial Controller at a multinational technology provider.
Entero Therapeutics (Nasdaq: ENTO) has announced the appointment of Richard Paolone as interim CEO. Paolone, a Toronto-based securities lawyer, brings extensive experience in corporate finance, securities law, and mergers and acquisitions to the clinical-stage biopharmaceutical company.
Paolone's background includes advising on strategic business initiatives, representing companies in debt and equity securities offerings, and demonstrating comprehensive knowledge of capital markets and regulatory environments. He has been instrumental in numerous M&A and go-public transactions, and has served as a director or officer for multiple private and publicly traded companies.
Entero Therapeutics (NASDAQ: ENTO) has secured a $2 million revolving loan agreement and appointed three new Board members. The loan agreement required the replacement of three out of five Board members with directors designated by the lender. James Sapirstein, Alastair Riddell, and Timothy Ramdeen have resigned from the Board.
The new appointees are: Richard Paolone, a Toronto-based securities lawyer; Eric Corbett, a managing director with capital markets experience; and Manpreet Uppal, a professional with capital markets and real estate expertise. The financing aims to strengthen the company's balance sheet and provide working capital while bridging to an anticipated subsequent public offering.
Entero Therapeutics (NASDAQ: ENTO) announced a binding term sheet for a reverse merger with Journey Therapeutics, a clinical-stage biopharmaceutical company. The merger will create a Nasdaq-listed company focused on Journey's nano-immunoconjugates (NIC) platform and Entero's gastrointestinal pipeline. Journey shareholders will acquire 99% of Entero's equity. The combined company will operate as Journey Therapeutics, led by Henry Ji, Ph.D. The NIC platform, licensed from Mayo Clinic, combines nanoparticle albumin-bound paclitaxel with tumor-targeting antibodies and chemotherapeutic toxins. The merger requires at least $5 million in equity financing and stockholder approval.
Entero Therapeutics (NASDAQ: ENTO) has signed a binding letter of intent with Data Vault Holdings to exclusively license two technology product suites - QOLPOM® and FotoDigm® - for clinical trial compliance. The deal aims to integrate these applications in Entero's planned Phase 3 study of latiglutenase for celiac disease. Key points:
1. Entero will receive global rights to pilot and commercialize the technology.
2. Payment includes convertible preferred stock and single-digit royalties.
3. The deal is contingent on securing at least $500K in strategic investment.
4. Closing is expected by the end of September.
5. The technology could improve clinical trial outcomes and has potential for broader commercial applications.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on gastrointestinal (GI) diseases, has received a notification from Nasdaq regarding its delayed Form 10-Q filing. The company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the late submission of its quarterly report for the period ended June 30, 2024.
Entero Therapeutics has until October 21, 2024, to submit a compliance plan to Nasdaq. If approved, the company may receive an extension until February 17, 2025, to regain compliance. The delay is attributed to the resignation of Forvis Mazars, LLP as the company's independent auditors on August 9, 2024. Entero Therapeutics is currently seeking a new accounting firm and aims to file the Form 10-Q before the October deadline.
Entero Therapeutics (NASDAQ: ENTO) has provided a business update focusing on its lead product candidate, latiglutenase, for celiac disease treatment. The company plans to advance latiglutenase into a pivotal Phase 3 trial in 2025. Key developments include:
1. Submitting two Type D meeting requests to the FDA to optimize the Phase 3 trial design.
2. Proposing to reduce cohorts from three to two (1200 mg and placebo) to maximize efficacy and potentially reduce costs and trial duration.
3. Preparing to finalize histology-related secondary efficacy endpoints.
4. Streamlining the trial design to focus on severe and symptomatic patients with intestinal damage.
5. Completing a small financing of $1.9 million in gross proceeds.
6. Consolidating operations to the Boca Raton headquarters to reduce costs and improve efficiency.